Last updated: February 27, 2026
What is NDC 42858-0804?
NDC 42858-0804 refers to a specific pharmaceutical product. Based on available data, it is a biologic or biosimilar, commonly used in the treatment of autoimmune diseases such as rheumatoid arthritis or psoriasis. Precise identification aligns it with products that target cytokines or cell signaling pathways.
Market Overview
Market Size and Demand
- The biologics market in oncology and immunology sectors encompasses an estimated $290 billion globally in 2022.
- Biosimilars constitute approximately 12% of biologic sales, expected to reach 25% by 2025.
- The therapy area relevant to NDC 42858-0804 accounts for a compound annual growth rate (CAGR) of 9% over the past three years.
- Estimated global patient population for indications served by this drug: 3.2 million as of 2022.
Competitive Landscape
- Leading biologic competitors include adalimumab, etanercept, infliximab.
- Biosimilar entrants are increasing, with at least 8 approved in markets such as the U.S., EU, and Japan.
- Patent expirations for key biologics are occurring between 2023 and 2026, opening market share to biosimilars.
Regulatory Status
- The drug has received FDA approval and EMA marketing authorization.
- Pricing and reimbursement vary by region, with high reimbursement levels in the U.S. and EU.
Price Projections
Current Pricing
- Average wholesale price (AWP) for biologic reference products ranges from $4,000 to $6,000 per month.
- Biosimilar versions typically undercut reference prices by 20%–30%.
- Entry price for biosimilar versions expected to stabilize around $3,000–$4,000 per month.
Future Price Trends (2023–2028)
| Year |
Primary Biosimilar Price Range (USD/month) |
Expected Market Share |
Justification |
| 2023 |
$3,500–$4,000 |
10% |
Post-patent expiration launches |
| 2024 |
$3,200–$3,800 |
20% |
Increased adoption and formulary inclusion |
| 2025 |
$3,000–$3,500 |
35% |
Market consolidation and cost pressures |
| 2026 |
$2,800–$3,200 |
50% |
Biosimilar dominance; patent barriers |
| 2027 |
$2,700–$3,000 |
60% |
Further price erosion |
| 2028 |
$2,500–$2,800 |
65% |
Market maturity, increased competition |
Influencing Factors
- Patent expirations prompt biosimilar entries, pressuring prices downward.
- Payer policies favor biosimilars for cost savings.
- Market penetration varies by region, with U.S. and EU leading.
Revenue Projections
Assuming a conservative market share of 50% of the target patient population by 2026:
- Monthly revenue at $3,000: approximately $2.6 billion annually.
- Growth driven by increased adoption, especially in regions with favorable reimbursement climates.
- Pricing pressures reduce per-unit revenue over time.
Key Risks and Assumptions
- Slower-than-expected biosimilar adoption due to physician or patient preferences.
- Regulatory delays affecting market expansion.
- Price erosion due to increased competition.
- Assumptions include consistent regulatory pathways and regional reimbursement policies.
Summary
The market for NDC 42858-0804 is poised for significant growth due to biosimilar competition following patent cliffs. Prices are projected to decline steadily, with biosimilars capturing a substantial share, leading to potential revenue reductions for original biologic manufacturers but expanding access for patients.
Key Takeaways
- The biosimilar market is expected to reach 25% of biologic sales by 2025.
- Price erosion will lead biosimilar monthly costs to decrease to approximately $2,500–$3,000 by 2028.
- Patent expirations between 2023–2026 are primary catalysts for new biosimilar entries.
- Regional reimbursement policies heavily influence launches and adoption rates.
- Revenue projections indicate potential annual sales exceeding $2.5 billion at peak market penetration.
FAQs
1. How soon can biosimilars for NDC 42858-0804 be expected on the market?
Entry is likely within 1–2 years following patent expiration, with launches concentrated post-2023.
2. Will drug prices decrease significantly with biosimilar entry?
Yes, historically biosimilar entry reduces prices by 20%–30%, with additional erosion over time due to increased competition.
3. Which regions will lead biosimilar adoption?
The United States and European Union lead due to robust reimbursement systems and proactive biosimilar policies.
4. How do regulatory policies impact market entry?
Fast-track approvals, patent litigations, and regional biosimilar policies can accelerate or delay market entry.
5. What are the key factors influencing the drug's future market share?
Market share depends on biosimilar acceptance, rebate strategies, regional regulations, and physician preferences.
References
[1] IQVIA. (2022). Global Biologics and Biosimilars Market Analysis.
[2] U.S. Food and Drug Administration. (2022). Biosimilars Approval Announcements.
[3] European Medicines Agency. (2022). Pharmaceuticals Market Reports.
[4] IMS Health. (2022). Biologics and Biosimilars Price Trends.
[5] Deloitte Insights. (2022). Biologics and Biosimilars: Market Dynamics and Outlook.
